Omega Healthcare Investors Inc.
OHI
$43.75
-2.28%
Omega Healthcare Investors Inc. is a real estate investment trust (REIT) that invests in healthcare-related real estate properties, primarily skilled nursing facilities, assisted living facilities, and other healthcare assets across the United States, the United Kingdom, and Canada. The company positions itself as the preferred capital partner to third-party healthcare operators, allowing them to focus on patient care while Omega owns and leases the underlying real estate. As a pure-play healthcare REIT with a market capitalization of approximately $14.1 billion, Omega is a bellwether in the skilled nursing facility (SNF) space, though its fortunes are closely tied to operator reimbursement trends, occupancy rates, and regulatory changes. The current investor narrative centers on the company's ability to sustain its high dividend yield (nearly 6%) amid a challenging interest rate environment, while recent news highlights broader sector consolidation—such as PACS's 32-facility Florida acquisition—which could signal both competitive pressures and opportunities for Omega to expand its portfolio or renegotiate leases.…
OHI
Omega Healthcare Investors Inc.
$43.75
Related headlines
Investment Opinion: Should I buy OHI Today?
Based on the synthesis of analyst consensus, valuation, and growth metrics, OHI warrants a Hold rating with a slight bullish tilt. The consensus recommendation is Buy (mean rating 2.4) with an average target price of $51.89, implying 13.5% upside, but the stock's recent underperformance and high payout ratio suggest caution. The core thesis is that OHI offers a stable income stream with a 5.94% dividend yield and solid free cash flow coverage, but near-term headwinds limit significant capital appreciation.
Supporting evidence includes revenue growth of 16.68% year-over-year in Q1 2026, a net margin of 46.77%, and trailing twelve-month free cash flow of $907.05 million. The dividend yield of 5.94% is attractive in a yield-starved environment, and the low beta of 0.567 provides defensive characteristics. However, the forward PE of 22.61x is above the trailing PE of 21.95x, indicating expected earnings decline, and the price-to-sales ratio of 10.96x is high relative to peers. The payout ratio of 132.24% is a red flag, though cash flow coverage mitigates immediate concerns.
The biggest risks that could invalidate the thesis are a deterioration in operator health leading to rent collection issues, a significant rise in interest rates increasing borrowing costs, and regulatory changes cutting Medicare/Medicaid reimbursement. The rating would upgrade to Buy if the payout ratio falls below 100% or if revenue growth accelerates above 20%, and it would downgrade to Sell if free cash flow declines below $800 million or if the dividend is cut. Relative to its history, OHI is fairly valued at 21.95x trailing PE, near the midpoint of its two-year range, and the stock appears appropriately priced given its stable but unspectacular growth outlook.
Sign up to view all
OHI 12-Month Price Forecast
OHI presents a balanced risk-reward profile, with strong revenue growth and an attractive dividend yield offset by a high payout ratio and near-term momentum headwinds. The analyst consensus is moderately bullish, but the stock's recent underperformance and premium valuation relative to peers suggest limited upside in the near term. The base case is most likely, with a target range of $46.00 to $51.89, assuming steady growth and no major disruptions. I would upgrade to bullish if the payout ratio falls below 100% or if revenue growth accelerates above 20%, and downgrade to bearish if free cash flow declines below $800 million or if operator health deteriorates significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Omega Healthcare Investors Inc.'s 12-month outlook, with a consensus price target around $51.78 and implied upside of +18.4% versus the current price.
Average Target
$51.78
0 analysts
Implied Upside
+18.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$46 - $61
Analyst target range
OHI is covered by 18 analysts, with a consensus recommendation of "Buy" (mean rating of 2.4 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average price target is $51.89, which implies an upside of approximately 13.5% from the current price of $45.72. The consensus leans moderately bullish, but the distribution of ratings is skewed toward Hold: recent actions include Barclays downgrading to Underweight in July 2026, while UBS and Citigroup maintain Buy ratings. This mixed sentiment suggests that while analysts see value, they are cautious about near-term headwinds such as interest rates and operator challenges.
The target price range spans from a low of $46.00 to a high of $61.00. The high target of $61.00 would require a re-rating of the multiple or significant growth acceleration, potentially driven by accretive acquisitions or a favorable reimbursement environment. The low target of $46.00 is only marginally above the current price, implying that even the bear case sees limited downside, likely due to the stock's defensive characteristics and high dividend yield. The wide spread of $15.00 between the low and high targets signals considerable uncertainty about the company's future performance, which is typical for a REIT with exposure to regulatory and operator-specific risks. Institutional ratings show a mix of upgrades and downgrades, with no clear directional trend, indicating that analysts are divided on the stock's near-term trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: OHI Investment Factors
The bull case for OHI rests on its robust 16.68% year-over-year revenue growth, attractive 5.94% dividend yield, and strong free cash flow of $907.05 million that comfortably covers dividend payments. The analyst consensus is a Buy with a $51.89 average target, implying 13.5% upside, and the low beta of 0.567 appeals to income-focused investors seeking stability. However, the bear case highlights a concerning 132.24% GAAP payout ratio, negative short-term momentum with 7.45% three-month underperformance, and a forward PE of 22.61x that suggests earnings decline. The most important tension is whether OHI can sustain its dividend and revenue growth amid operator challenges and interest rate pressures; if free cash flow remains strong and the payout ratio improves, the bull case prevails, but any deterioration in operator health or reimbursement could quickly shift sentiment. Currently, the bull evidence is slightly stronger due to solid cash flow coverage and analyst support, but the stock's recent underperformance and high payout ratio warrant caution.
Bullish
- Revenue growth accelerating at 16.7% YoY: Q1 2026 revenue of $322.96 million rose 16.68% from $276.79 million in Q1 2025, marking the strongest annual comparison in recent quarters. This growth was driven by acquisitions, rent escalations, and portfolio optimization, and it outpaced the broader REIT sector's typical low-single-digit growth.
- Attractive 5.94% dividend yield with solid FCF coverage: OHI offers a 5.94% dividend yield, well above the S&P 500 average, and generated $907.05 million in trailing twelve-month free cash flow. This FCF comfortably covers the roughly $198 million in quarterly dividend payments, implying a cash-flow-based payout ratio of about 87%, which is more sustainable than the GAAP payout ratio of 132% suggests.
- Analyst consensus Buy with 13.5% upside: 18 analysts rate OHI a Buy (mean rating 2.4) with an average price target of $51.89, implying 13.5% upside from the current $45.72. The low target of $46.00 is only marginally above the current price, indicating limited downside even in the bear case.
- Low beta of 0.567 offers defensive characteristics: OHI's beta of 0.567 means it is roughly 43% less volatile than the broader market, making it an attractive income vehicle for risk-averse investors. The maximum drawdown of -12.55% over the past year is relatively contained, consistent with this low-beta profile.
Bearish
- Dividend payout ratio of 132% raises sustainability concerns: The dividend payout ratio of 132.24% means OHI is paying out more in dividends than it earns on a GAAP basis, which could pressure the dividend if earnings decline. While free cash flow covers the payout, the high ratio leaves little margin for error if operator rent collections weaken.
- Negative short-term momentum and relative underperformance: OHI has declined 2.70% over the past month and 7.45% over the past three months, significantly underperforming the S&P 500 by 3.29% and 10.79% respectively. This deceleration suggests capital is rotating away from the name, and the stock is trading 12.7% below its 52-week high of $52.39.
- Forward PE of 22.61x implies earnings decline: The forward PE of 22.61x is higher than the trailing PE of 21.95x, indicating that analysts expect earnings to decline over the next year. This narrow gap suggests the market is not pricing in growth acceleration, and the valuation is near the midpoint of its recent historical range of 16.75x to 27.99x.
- High PS ratio of 10.96x relative to sector: OHI's price-to-sales ratio of 10.96x is relatively high for a healthcare REIT, reflecting the capital-intensive nature of its business. This premium valuation leaves little room for disappointment, especially if revenue growth moderates from the current 16.68% pace.
OHI Technical Analysis
OHI has been in a broad consolidation phase over the past year, with a 1-year price change of +9.85% that masks significant volatility. The stock is currently trading at $45.72, which is only 37.6% above its 52-week low of $39.26 and 12.7% below its 52-week high of $52.39, placing it in the lower-middle portion of its annual range. This positioning suggests neither a strong momentum breakout nor a deep value opportunity, but rather a market that is waiting for a clearer fundamental catalyst. The 52-week range itself is relatively wide at $13.13, implying that the stock has experienced meaningful swings despite the modest net gain.
Short-term momentum has turned negative, with a 1-month decline of 2.70% and a 3-month drop of 7.45%, contrasting sharply with the positive 1-year return. This divergence indicates a deceleration in the uptrend that had been in place earlier in the year, and the recent pullback may be a mean-reversion move after the stock hit its 52-week high in July 2026. Relative strength metrics confirm underperformance: OHI has lagged the S&P 500 by 3.29% over the past month and by 10.79% over the past three months, suggesting that capital is rotating away from the name. The 6-month change of +1.6% is barely positive, further evidence that momentum has stalled since the spring.
Key technical levels to watch are the 52-week low of $39.26 as support and the 52-week high of $52.39 as resistance. A breakdown below $39.26 would signal a bearish trend reversal and could trigger further selling, while a breakout above $52.39 would confirm a new leg higher. The stock's beta of 0.567 indicates it is significantly less volatile than the broader market—roughly 43% less volatile than SPY—which may appeal to risk-averse income investors but also means it may lag in strong bull markets. The maximum drawdown of -12.55% over the past year is relatively contained, consistent with the low-beta profile.
Beta
0.53
0.53x market volatility
Max Drawdown
-15.4%
Largest decline past year
52-Week Range
$39-$52
Price range past year
Annual Return
+6.6%
Cumulative gain past year
| Period | OHI Return | S&P 500 |
|---|---|---|
| 1m | -5.7% | +0.9% |
| 3m | -10.4% | +3.4% |
| 6m | -4.5% | +14.4% |
| 1y | +6.6% | +16.2% |
| ytd | -1.8% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OHI Fundamental Analysis
OHI's revenue trajectory has been steadily improving, with the most recent quarter (Q1 2026) showing revenue of $322.96 million, a 16.68% year-over-year increase from $276.79 million in Q1 2025. This growth is part of a multi-quarter uptrend: revenue rose from $282.51 million in Q2 2025 to $311.59 million in Q3 2025, $321.82 million in Q4 2025, and $322.96 million in Q1 2026. The sequential growth has moderated, but the annual comparison remains robust, driven by acquisitions, rent escalations, and portfolio optimization. The company's revenue mix is heavily weighted toward its issuer and subsidiary guarantors segment, which generated $71.16 million, while non-guarantor subsidiaries contributed $13.35 million, indicating a concentrated but stable revenue base.
Profitability is strong for a REIT, with Q1 2026 net income of $151.05 million and a net margin of 46.77%. Gross margin was reported at 97.21% in Q1 2026, though this metric can be volatile due to property-level accounting; the operating margin was 64.12%, reflecting efficient management of property operating costs. Over the past four quarters, net income has ranged from $136.60 million to $179.72 million, with the net margin fluctuating between 46.77% and 57.68%. The company's return on equity (ROE) stands at 11.39%, which is respectable for a REIT and indicates effective use of shareholder capital. The dividend payout ratio of 132.24% is above 100%, meaning the company is paying out more in dividends than it earns, which could be a concern if not supported by cash flow.
Balance sheet health is solid, with a debt-to-equity ratio of 0.82 and a current ratio of 3.46, indicating ample liquidity. The company generated $907.05 million in trailing twelve-month free cash flow, which comfortably covers its dividend payments (approximately $198 million per quarter). The FCF yield, based on the current market cap of $13.13 billion, is roughly 6.9%, a healthy level for an income-oriented REIT. However, the debt-to-equity ratio, while moderate, still exposes the company to interest rate risk, especially with $49.76 million in quarterly interest expense. The cash flow statement shows consistent operating cash flow above $200 million per quarter, providing internal funding for capital expenditures and dividends without heavy reliance on external financing.
Quarterly Revenue
$322955000.0B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
97.2%
Latest Quarter
Free Cash Flow
$907053000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OHI Overvalued?
Because OHI is profitable with positive net income, the PE ratio is the primary valuation metric. The trailing PE is 21.95x, while the forward PE is 22.61x, implying a slight expected decline in earnings over the next year. This narrow gap suggests that the market is not pricing in significant growth acceleration; rather, it reflects stable, income-oriented expectations. The price-to-sales (PS) ratio is 10.96x, and the price-to-book (PB) ratio is 2.53x, both of which are relevant for asset-heavy REITs.
Compared to the broader REIT sector, OHI's valuation appears mixed. The sector average PE for healthcare REITs typically ranges between 15x and 25x, so OHI's 21.95x is near the middle of that range. However, its PS ratio of 10.96x is relatively high, reflecting the capital-intensive nature of its business and the premium the market assigns to its stable cash flows. The dividend yield of 5.94% is attractive in a yield-starved environment, but the payout ratio of 132% raises questions about sustainability. The PB ratio of 2.53x is above the sector median of around 2.0x, suggesting that investors are willing to pay up for OHI's portfolio quality and operator relationships.
Historically, OHI's PE ratio has ranged from a low of 9.86x in Q1 2022 to a high of 52.84x in Q4 2021, with a more recent range of 16.75x to 27.99x over the past two years. The current 21.95x is near the midpoint of that recent range, indicating that the stock is neither cheap nor expensive relative to its own history. The PS ratio has been more stable, fluctuating between 28x and 45x over the past five years, and the current 10.96x is significantly lower, but this is due to changes in revenue recognition and should be interpreted with caution. Overall, the valuation appears fair, with the market pricing in steady but unspectacular growth.
PE
22.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 10x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
OHI faces financial and operational risks primarily stemming from its high dividend payout ratio of 132.24%, which exceeds GAAP earnings and could pressure the dividend if cash flow declines. The company's debt-to-equity ratio of 0.82 and quarterly interest expense of $49.76 million expose it to interest rate risk, especially if refinancing occurs in a higher-rate environment. Additionally, revenue concentration in the issuer and subsidiary guarantors segment ($71.16 million) creates dependence on a limited set of operators, making OHI vulnerable to tenant defaults or bankruptcies. While trailing twelve-month free cash flow of $907.05 million provides coverage, any decline in occupancy or rent collections could quickly erode this cushion.
Market and competitive risks include OHI's premium valuation, with a price-to-sales ratio of 10.96x and price-to-book ratio of 2.53x, both above sector medians, leaving little room for disappointment. The stock's beta of 0.567 indicates lower volatility than the market, but it has underperformed the S&P 500 by 10.79% over three months, suggesting sector rotation away from healthcare REITs. Recent news of PACS's 32-facility Florida acquisition highlights consolidation in the skilled nursing space, which could intensify competition for assets and pressure lease terms. Regulatory changes in Medicare and Medicaid reimbursement also pose a persistent threat, as any cuts would directly impact operator profitability and, by extension, OHI's rent collections.
In a worst-case scenario, a combination of operator defaults, reimbursement cuts, and rising interest rates could trigger a sharp decline. The 52-week low of $39.26 represents a 14.1% downside from the current price of $45.72, and the analyst low target of $46.00 is only marginally above the current price, suggesting limited downside according to analysts. However, if dividend sustainability concerns escalate and the payout ratio remains above 100%, the stock could test its 52-week low, implying a loss of approximately 14% from current levels. A more severe scenario involving multiple operator bankruptcies could push the stock below $39.26, but the low beta and defensive nature of healthcare REITs may limit the damage compared to broader market selloffs.
FAQ
The most severe risk is the high dividend payout ratio of 132.24%, which could lead to a dividend cut if earnings decline. Operator concentration risk is significant, with the issuer and subsidiary guarantors segment generating $71.16 million, exposing OHI to tenant defaults. Interest rate risk is also material, as the debt-to-equity ratio of 0.82 and quarterly interest expense of $49.76 million make the company sensitive to rising rates. Finally, regulatory changes in Medicare/Medicaid reimbursement could pressure operator profitability and, consequently, OHI's rent collections.
The 12-month forecast for OHI includes a base case (55% probability) with a target range of $46.00 to $51.89, assuming steady revenue growth and stable dividends. The bull case (25% probability) targets $52.39 to $61.00, driven by accretive acquisitions and favorable reimbursement trends. The bear case (20% probability) targets $39.26 to $46.00, reflecting operator defaults or reimbursement cuts. The most likely scenario is the base case, with the key assumption that free cash flow remains above $850 million and covers the dividend.
OHI appears fairly valued, with a trailing PE of 21.95x near the midpoint of its two-year range of 16.75x to 27.99x. The price-to-sales ratio of 10.96x is high relative to peers, but the price-to-book ratio of 2.53x is only slightly above the sector median of 2.0x. The forward PE of 22.61x suggests the market expects flat to declining earnings, which may be conservative given the 16.68% revenue growth. Overall, the valuation reflects stable, income-oriented expectations rather than significant growth, and the stock is not cheap but not excessively expensive.
OHI can be a good buy for income-focused investors seeking a high dividend yield of 5.94% and low volatility, as indicated by its beta of 0.567. The analyst consensus is Buy with an average target of $51.89, implying 13.5% upside, and the company generates strong free cash flow of $907.05 million. However, the high payout ratio of 132.24% and recent underperformance relative to the S&P 500 raise concerns about near-term total return. It is best suited for patient investors who prioritize income over capital appreciation and can tolerate the risks associated with healthcare REITs.
OHI is more suitable for long-term investment, given its low beta of 0.567, stable dividend yield of 5.94%, and the nature of healthcare REITs as income-generating assets. Short-term trading is less attractive due to the stock's recent negative momentum, with a 7.45% decline over three months and underperformance versus the S&P 500. The company's earnings visibility is moderate, with revenue growth driven by long-term leases and an aging population. A minimum holding period of 2-3 years is recommended to capture the dividend income and potential capital appreciation as the portfolio matures.
